SCHEMBL23590339

SCHEMBL23590339

CCCOc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(C(F)(F)F)ccc4n3)cc2F)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 6/20 0.60
▸ PDE10A Q9Y233 1/20 0.57
▸ PLA2G2A P14555 3/20 0.52
▸ EIF4A1 P60842 2/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALOX5AP P20292 1/20 0.46
▸ FEN1 P39748 1/20 0.46
▸ PPARD Q03181 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590335 0.96 DHODH (0.55) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590284 0.95 DHODH (0.53) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590282 0.94 DHODH (0.52) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590275 0.94 DHODH (0.52) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590283 0.94 DHODH (0.52) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590130 0.94 DHODH (0.52) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590263 0.93 DHODH (0.51) DHODHPDE10APLA2G2AEIF4A1KDM4E
SCHEMBL23590285 0.93 KDM4E (0.56) DHODHPDE10AEIF4A1KDM4ESMN1; SMN2
SCHEMBL23590260 0.92 DHODH (0.49) DHODHPDE10APLA2G2AKDM4ESMN1; SMN2
SCHEMBL23590132 0.90 DHODH (0.48) DHODHPDE10APLA2G2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
WO-2023278778-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-01-05 — — WO disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021134042-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885PDE10A 3462/4885PLA2G2A 1679/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH DHODH 1/4885PDE10A 3672/4885PLA2G2A 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback